Stock events for BioLife Solutions, Inc. (BLFS)
In the past six months, BioLife Solutions reported a 29% increase in total revenue for 2025 and projected 17-20% revenue growth for 2026. Despite positive guidance, the stock declined over 10% on March 4, 2026, possibly due to a "sell the news" reaction. A multi-year supply agreement with Qkine Limited was signed to expand into the cytokines market. The stock's 52-week range has been between $19.10 and $29.62. As of March 5, 2026, the share price was $23.09, a 10.23% decline over the past year. The company reported a GAAP net loss of $12.1 million for 2025, despite a profitable Q4.
Demand Seasonality affecting BioLife Solutions, Inc.’s stock price
While seasonality analysis is mentioned in a general context for BLFS stock, specific details or patterns regarding demand seasonality for BioLife Solutions' products and services are not available.
Overview of BioLife Solutions, Inc.’s business
BioLife Solutions, Inc. is a life sciences company focused on bioproduction products and services for the cell and gene therapy and broader biopharma markets. It operates within the Surgical and Medical Instrument Manufacturing industry and is considered a pure-play cell processing company. The company's offerings include cell processing tools, biopreservation media like CryoStor® and HypoThermosol®, CellSeal® cryogenic vials, hPL products, CryoCase containers, and ThawSTAR® devices. These products are used in clinical trials and approved cell and gene therapies.
BLFS’s Geographic footprint
BioLife Solutions, Inc. has a geographic presence in the United States, Europe, the Middle East, and Africa, with the majority of its revenue coming from the United States. The company is considering expanding into underpenetrated markets like Asia-Pacific for plasma-derived therapies. The corporate office is located in Bothell, Washington, United States.
BLFS Corporate Image Assessment
BioLife Solutions maintains a strong brand reputation as a key player in the cell and gene therapy market. Its products are integrated into the manufacturing process of cell and gene therapies, specified in over 70% of U.S. cell-based therapy clinical trials, and used in approximately 90% of commercially relevant FDA-approved cell-based therapies. The company has refocused its portfolio by divesting non-core businesses to emphasize cell processing tools and services, supported by acquisitions like PanTHERA CryoSolutions and an investment in Pluristyx.
Ownership
Institutional investors are the dominant force in BioLife Solutions' ownership, holding a substantial portion of the company's shares. As of March 5, 2026, 355 institutional owners and shareholders held a total of 54,362,491 shares. Major institutional owners include Casdin Capital, LLC, BlackRock, Inc., Invesco Ltd., Vanguard Group Inc., T. Rowe Price Investment Management, Inc., and State Street Corp. Institutional ownership accounts for approximately 93.24% of the stock, while insider ownership stands at 2.20%.
